ASCO 2024: Innovent Biologics Delivers Oral Presentation of Clinical Data of a Randomized Controlled Phase 1b Study Evaluating IBI310 in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer

Innovent Biologics Announcement at ASCO
Innovent Biologics , Inc. (HKEX: 01801)(OTC: IVBXFannounced that the clinical . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.